Scarica l'app Stockscreener
9.1476
5.82%
0.4776
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TLRY Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.67
Aprire:
$8.79
Volume 24 ore:
2.42M
Relative Volume:
0.25
Capitalizzazione di mercato:
$1.07B
Reddito:
$829.22M
Utile/perdita netta:
$-248.96M
Rapporto P/E:
-30.49
EPS:
-0.3
Flusso di cassa netto:
$-92.10M
1 W Prestazione:
-5.51%
1M Prestazione:
-11.95%
6M Prestazione:
+16.75%
1 anno Prestazione:
-18.81%
Intervallo 1D:
$8.76
$9.19
Intervallo di 1 settimana:
$8.61
$9.6799
Portata 52W:
$3.507
$23.20
Tilray Brands Inc Stock (TLRY) Company Profile
Nome
Tilray Brands Inc
Settore
Telefono
519.322.8800
Indirizzo
655 MADISON AVENUE, NEW YORK
Confronta TLRY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TLRY
Tilray Brands Inc
|
9.1501 | 1.01B | 829.22M | -248.96M | -92.10M | -0.30 |
|
ZTS
Zoetis Inc
|
124.41 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.00 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.31 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.75 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
468.37 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Tilray Brands Inc Stock (TLRY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-05 | Reiterato | Alliance Global Partners | Neutral |
| 2022-11-02 | Iniziato | Bernstein | Mkt Perform |
| 2022-07-29 | Downgrade | The Benchmark Company | Hold → Sell |
| 2022-03-04 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-11-18 | Iniziato | Barclays | Underweight |
| 2021-11-01 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-06-11 | Downgrade | CIBC | Sector Outperform → Neutral |
| 2021-06-03 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-05-11 | Ripresa | Cowen | Outperform |
| 2021-05-07 | Ripresa | Jefferies | Buy |
| 2021-05-06 | Iniziato | Canaccord Genuity | Buy |
| 2021-04-28 | Ripresa | BofA Securities | Buy |
| 2021-02-18 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-18 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-11-16 | Downgrade | Jefferies | Hold → Underperform |
| 2020-11-11 | Downgrade | Stifel | Hold → Sell |
| 2020-10-01 | Reiterato | MKM Partners | Neutral |
| 2020-09-21 | Aggiornamento | Jefferies | Underperform → Hold |
| 2020-05-12 | Reiterato | The Benchmark Company | Buy |
| 2020-04-16 | Downgrade | Jefferies | Hold → Underperform |
| 2020-04-09 | Downgrade | Consumer Edge Research | Overweight → Equal Weight |
| 2020-02-24 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-01-13 | Iniziato | BofA/Merrill | Neutral |
| 2019-11-13 | Reiterato | The Benchmark Company | Buy |
| 2019-11-05 | Iniziato | Cantor Fitzgerald | Neutral |
| 2019-10-22 | Reiterato | Piper Jaffray | Overweight |
| 2019-09-20 | Iniziato | MKM Partners | Neutral |
| 2019-08-14 | Reiterato | The Benchmark Company | Buy |
| 2019-07-17 | Iniziato | Ladenburg Thalmann | Neutral |
| 2019-06-28 | Iniziato | Consumer Edge Research | Overweight |
| 2019-06-06 | Iniziato | Stifel | Hold |
| 2019-06-05 | Iniziato | Oppenheimer | Perform |
| 2019-05-15 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2019-05-13 | Iniziato | Alliance Global Partners | Neutral |
Mostra tutto
Tilray Brands Inc Borsa (TLRY) Ultime notizie
What's Going On With Tilray Stock Today? - Benzinga
Tilray (TLRY) Expands Medical Cannabis Operations in Italy - GuruFocus
New 9% 'Big Trip' IPA rides Southeast double-IPA demand - Stock Titan
Tilray Medical Launches Tilray Medical Italia, Expanding Presence in Italy's Medical Cannabis Market - Quiver Quantitative
Tilray brings prescription cannabis oils and flower to Italian patients - Stock Titan
Promising Cannabis Stocks To Watch TodayJanuary 21st - MarketBeat
Tilray’s Financial Turnaround: Losses Narrow Amidst Strategic Shifts - AD HOC NEWS
Tilray Brands Just Posted Record Numbers for Q2. Is the Stock a Buy? - AOL.com
Tilray Brands (NASDAQ:TLRY) Trading Down 7.4% Following Analyst Downgrade - MarketBeat
Tilray Brands (TLRY): Roth Capital Lowers Price Target to $10 | - GuruFocus
Tilray Brands (NASDAQ:TLRY) Given New $10.00 Price Target at Roth Capital - MarketBeat
Mixed Signals for Tilray: Record Revenue Meets Analyst Caution - AD HOC NEWS
How Tilray Brands Is Acting on Its Vast International Opportunity - The Globe and Mail
Tilray Brands Reports $218 Million Q2 Revenue, Market Reacts Positively - Intellectia AI
Tilray Brands, Inc. (NASDAQ:TLRY) Given Consensus Rating of "Reduce" by Brokerages - MarketBeat
This Beaten-Down Stock Just Posted Record Revenue. Is It Finally Time to Buy? - Finviz
Top Cannabis Stocks To Follow TodayJanuary 19th - MarketBeat
Tilray’s Mixed Quarter: Record Revenue Overshadowed by Widening Losses - AD HOC NEWS
Tilray. Buy, Sell or Hold? - Cantech Letter
Trump's Cannabis Rescheduling Order Could Finally Kill A Crushing Tax Rule And Transform US Weed Stocks, Says Expert - Benzinga
Tilray Shares Face Headwinds Following Quarterly Report - AD HOC NEWS
Tilray Shares Face Mounting Investor Skepticism Despite Revenue Gains - AD HOC NEWS
Promising Cannabis Stocks To Keep An Eye OnJanuary 18th - MarketBeat
Tilray’s Financial Paradox: Record Revenue Amid Persistent Losses - AD HOC NEWS
Best Cannabis Stocks To ResearchJanuary 17th - MarketBeat
Tilray’s Financial Results Reveal Deepening Concerns for Investors - AD HOC NEWS
Tilray anticipates $150M global medical cannabis revenue run rate as international expansion accelerates - MSN
Tilray Brands (NASDAQ:TLRY) Stock Price Down 2.6%Time to Sell? - MarketBeat
Top Cannabis Stocks To Add to Your WatchlistJanuary 16th - MarketBeat
Promising Cannabis Stocks To Add to Your WatchlistJanuary 3rd - MarketBeat
Village Farms Stock More Than Doubles in 6 Months: How to Play? - The Globe and Mail
Lacklustre Performance Is Driving Tilray Brands, Inc.'s (NASDAQ:TLRY) 30% Price Drop - simplywall.st
Tilray’s Profitability Concerns Overshadow Record Revenue - AD HOC NEWS
Tilray Continues to Gain in Canada and International Medical, but We're Skeptical of US Prospects - Morningstar
Tilray Brands (NASDAQ:TLRY) Shares Down 1.9%What's Next? - MarketBeat
Best Cannabis Stocks To Watch TodayJanuary 15th - MarketBeat
Tilray Brands (NASDAQ:TLRY) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
Tilray Brands (NASDAQ:TLRY) Trading Up 5.4%Here's What Happened - MarketBeat
Cannabis Stocks To Watch TodayJanuary 14th - MarketBeat
Tilray Posts Record Revenue Amid Diverging Segment Performance - AD HOC NEWS
What's Next for Tilray Brands After Posting Record Q2 Revenues? - The Globe and Mail
Tilray Brands (TSX:TLRY) Price Target Decreased by 18.79% to 19.17 - Nasdaq
Investment Recap: Why Tilray Brands Inc stock is seen as undervaluedJuly 2025 Summary & Detailed Earnings Play Alerts - moha.gov.vn
Top Cannabis Stocks To ResearchJanuary 13th - MarketBeat
Best Cannabis Stocks To Follow TodayJanuary 8th - MarketBeat
Should You Buy, Sell or Hold TLRY Stock Post Q2 Earnings? - The Globe and Mail
Legal Cannabis Market Set for Dynamic Growth with Key Players Aurora Cannabis • Cronos Group • Tilray Brands - openPR.com
This Under-$10 Growth Stock May Be Better Positioned Than Investors Realize - Barchart.com
Tilray Brands (XTRA:2HQ) Price Target Decreased by 23.26% to 11.31 - Nasdaq
Tilray Reports Historic Quarterly Revenue Amid Strategic Shifts - AD HOC NEWS
Tilray Brands (NASDAQ:TLRY) Shares Up 1.3%Still a Buy? - MarketBeat
Tilray Brands Inc Azioni (TLRY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Tilray Brands Inc Azioni (TLRY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SIMON IRWIN D | President and CEO |
Jul 31 '25 |
Option Exercise |
0.58 |
706,216 |
409,605 |
5,200,788 |
| Merton Carl A | Chief Financial Officer |
Jul 31 '25 |
Option Exercise |
0.58 |
93,928 |
54,478 |
970,279 |
| Gendel Mitchell | Global General Counsel |
Jul 31 '25 |
Option Exercise |
0.58 |
93,928 |
54,478 |
742,069 |
| Gendel Mitchell | Global General Counsel |
Jul 31 '25 |
Buy |
0.58 |
6,000 |
3,496 |
698,287 |
| FALTISCHEK DENISE M | Chief Strategy Officer |
Jul 31 '25 |
Option Exercise |
0.58 |
93,928 |
54,478 |
874,564 |
| FALTISCHEK DENISE M | Chief Strategy Officer |
Jul 30 '25 |
Option Exercise |
0.61 |
261,194 |
159,328 |
919,069 |
| Herhalt Johann Michael | Director |
Jul 30 '25 |
Option Exercise |
0.61 |
124,378 |
75,871 |
239,930 |
| Looney Thomas P. | Director |
Jul 30 '25 |
Option Exercise |
0.61 |
124,378 |
75,871 |
354,416 |
| Hopkinson David G. | Director |
Jul 30 '25 |
Option Exercise |
0.61 |
124,378 |
75,871 |
335,563 |
| Clanachan David F | Director |
Jul 30 '25 |
Option Exercise |
0.61 |
124,378 |
75,871 |
236,880 |
4.25%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):